Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

GLS 012

Next Previous
X
Search
Drug Profile

GLS 012

Alternative Names: GLS-012

Latest Information Update: 15 Aug 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Guangzhou Gloria Biosciences
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; CD223 antigen inhibitors; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Solid tumours

Most Recent Events

  • 10 Aug 2023 Guangzhou Gloria Biosciences plans phase I/II Triumph-02 trial in Non-Small Cell Lung Cancer (Late-stage disease, Combination therapy) in China (IV) (NCT05978401)
  • 21 Jun 2023 Guangzhou Gloria Biosciences has patents pending for "medicinal preparation and application thereof in treating liver cancer" in China
  • 12 Jun 2023 Center for Drug Evaluation of NMPA China approves IND application for GLS-012 in Solid tumours (Guangzhou Gloria Biosciences webite, June 2023)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top